Sagimet Biosciences schedules Sept. 30 KOL event on denifanstat acne program

The event will cover 52-week Phase 3 open-label extension data from China and an update on the planned U.S. AURORA Phase 3 acne trial. Sagimet targets U.S. AURORA trial initiation for Q4 2026.